SOR-CART-MM-001 Study: A Phase I, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Darzalex (daratumumab) - J&J

Blenrep (belantamab mafodotin-blmf) - GSK

anti-CD38 A2 CAR-T cells - Celularity, Sorrento

STI-1492 - Sorrento

cyclophosphamide - Generic mfg.

Edward A. Stadtmauer; Omar Elghawy; Todd F. Roberts; Deepu Madduri; Sikander Ailawadhi; Mike Royal; Ying Yan

Dec 3, 2023